Moderna's RSV vaccine based on mRNA technology is also expected to be approved soon.

Scientists from the University of Oxford, University of Cambridge, and The Pirbright Institute in the UK have discovered a potential new treatment approach for poxviruses like monkeypox and smallpox viruses.

Relaxin Family Peptide Receptor 1 (RXFP1) is the receptor of relaxin-2, and relaxin-2 is an important regulator of reproduction and cardiovascular physiology.

Interleukin-2 (IL-2) in particular has undergone extensive engineering attempts to generate IL-2 variants with selective activities.

METTL3 is an RNA methyltransferase that catalyzes the methylation of RNA at N6-adenosine, making it a key player in this process.

Researchers have made significant progress in understanding the role of NLRP3 signaling in the aging process of podocytes, a type of kidney cell.

The Y220C target mutation is a common oncogenic missense mutation, with a slightly lower mutation frequency compared to R249S and G245S located on the DNA binding surface.

Dolutegravir, a widely used antiretroviral drug, has shown excellent efficacy in treating HIV in adults. However, concerns have been raised about its potential neuropsychiatric side effects, which prompted the investigation into its impact on younger populations.

PI3Kα is a crucial lipid kinase and one of the most frequently mutated kinases in cancer. It consists of a heterodimer composed of the catalytic subunit p110α and the regulatory subunit p85α.

Lotilaner (Xdemvy), a small molecule drug that targets GluCls, was developed by Tarsus Pharma-ceuticals, Inc. and received FDA approval on July 24th, 2023 for the treatment of demodex blepharitis.

Glucose-dependent insulinotropic polypeptide (GIP) is one of two enteroinsular hormones, playing a crucial role in linking nutrient intake with whole-body metabolism.

FCN-159 is an orally effective selective MEK1/2 inhibitor and a prospective targeted therapy drug for tumors mutated by BRAF or RAS.